Nagaendran Kandiah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/76409/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clinical Interventions in Aging, 2017, Volume 12, 697-707.	1.3	143
2	Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurology, The, 2019, 18, 653-665.	4.9	143
3	Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of <i>Ginkgo biloba</i> extract, EGb 761 [®] . CNS Neuroscience and Therapeutics, 2019, 25, 288-298.	1.9	93
4	Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1203-1208.	1.1	83
5	Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer's disease mice. Scientific Reports, 2016, 6, 23964.	1.6	82
6	Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1145-1148.	1.1	73
7	Associations of hippocampal subfields in the progression of cognitive decline related to Parkinson's disease. NeuroImage: Clinical, 2017, 14, 37-42.	1.4	73
8	White Matter Disease Independently Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease in a Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2011, 31, 431-434.	0.7	68
9	Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. British Journal of Pharmacology, 2017, 174, 4224-4232.	2.7	67
10	Cerebral white matter hyperintensity in Parkinson's disease: A major risk factor for mild cognitive impairment. Parkinsonism and Related Disorders, 2013, 19, 680-683.	1.1	64
11	Light-Induced Pupillary Responses in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 360.	1.1	64
12	Subcortical Atrophy Is Associated with Cognitive Impairment in Mild Parkinson Disease: A Combined Investigation of Volumetric Changes, Cortical Thickness, and Vertex-Based Shape Analysis. American Journal of Neuroradiology, 2014, 35, 2257-2264.	1.2	63
13	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 2017, 88, 1814-1821.	1.5	61
14	Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 576-580.	0.9	58
15	Cognitive decline in early Parkinson's disease. Movement Disorders, 2009, 24, 605-608.	2.2	51
16	Effectiveness of Montreal Cognitive Assessment for the diagnosis of mild cognitive impairment and mild Alzheimer's disease in Singapore. Singapore Medical Journal, 2013, 54, 616-9.	0.3	48
17	Progression of subcortical atrophy in mild Parkinson's disease and its impact on cognition. European Journal of Neurology, 2017, 24, 341-348.	1.7	47
18	Alzheimer's disease with cerebrovascular disease: current status in the Asia–Pacific region. Journal of Internal Medicine, 2016, 280, 359-374	2.7	46

#	Article	IF	CITATIONS
19	Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score. Journal of Alzheimer's Disease, 2016, 49, 1169-1177.	1.2	44
20	Hyperglycemic choreoathetosis: Role of the putamen in pathogenesis. Movement Disorders, 2009, 24, 915-919.	2.2	42
21	STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 11-23.	1.2	41
22	Frontal subcortical ischemia is crucial for post stroke cognitive impairment. Journal of the Neurological Sciences, 2011, 309, 92-95.	0.3	40
23	Long-Term Cognitive Decline After Stroke: An Individual Participant Data Meta-Analysis. Stroke, 2022, 53, 1318-1327.	1.0	40
24	White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 754-760.	1.0	38
25	Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 413-423.	1.2	38
26	Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function. Parkinsonism and Related Disorders, 2015, 21, 1056-1060.	1.1	37
27	Development and validation of a risk score (CHANGE) for cognitive impairment after ischemic stroke. Scientific Reports, 2017, 7, 12441.	1.6	37
28	Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurology, The, 2021, 20, 294-303.	4.9	37
29	Carotid Stenosis: A Risk Factor for Cerebral White-matter Disease. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 136-139.	0.7	36
30	Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease. European Journal of Neurology, 2015, 22, 150-155.	1.7	36
31	Depression and anxiety are co-morbid but dissociable in mild Parkinson's disease: A prospective longitudinal study of patterns and predictors. Parkinsonism and Related Disorders, 2016, 23, 50-56.	1.1	34
32	Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease. Journal of the Neurological Sciences, 2017, 377, 122-126.	0.3	29
33	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. Expert Review of Neurotherapeutics, 2018, 18, 859-869.	1.4	29
34	Association of Prediabetes and Type 2 Diabetes With Cognitive Function After Stroke. Stroke, 2020, 51, 1640-1646.	1.0	29
35	Distinct network topology in Alzheimer's disease and behavioral variant frontotemporal dementia. Alzheimer's Research and Therapy, 2021, 13, 13.	3.0	29
36	Regional White Matter Hyperintensity Influences Grey Matter Atrophy in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 533-549.	1.2	28

#	Article	IF	CITATIONS
37	Cost Related to Dementia in the Young and the Impact of Etiological Subtype on Cost. Journal of Alzheimer's Disease, 2015, 49, 277-285.	1.2	27
38	Neural correlates of anxiety symptoms in mild Parkinson's disease: A prospective longitudinal voxel-based morphometry study. Journal of the Neurological Sciences, 2016, 371, 131-136.	0.3	27
39	Depressive symptoms influence global cognitive impairment indirectly by reducing memory and executive function in patients with mild cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1375-1383.	0.9	26
40	Postâ€ s troke subjective cognitive impairment is associated with acute lacunar infarcts in the basal ganglia. European Journal of Neurology, 2013, 20, 547-551.	1.7	25
41	Associations between lesions and domain-specific cognitive decline in poststroke dementia. Neurology, 2018, 91, e45-e54.	1.5	24
42	Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 681-687.	0.9	24
43	Longitudinal brain volumetric changes and their predictive effects on cognition among cognitively asymptomatic patients with Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 483-488.	1.1	23
44	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. Translational Neurodegeneration, 2021, 10, 1.	3.6	23
45	High Caregiver Burden in Young Onset Dementia: What Factors Need Attention?. Journal of Alzheimer's Disease, 2017, 61, 537-543.	1.2	22
46	Degenerative protein modifications in the aging vasculature and central nervous system: A problem shared is not always halved. Ageing Research Reviews, 2019, 53, 100909.	5.0	22
47	Cerebral Small Vessel Disease Influences Hippocampal Subfield Atrophy in Mild Cognitive Impairment. Translational Stroke Research, 2021, 12, 284-292.	2.3	22
48	Strategies for the use of <i>Ginkgo biloba</i> extract, EGb 761 [®] , in the treatment and management of mild cognitive impairment in Asia: Expert consensus. CNS Neuroscience and Therapeutics, 2021, 27, 149-162.	1.9	21
49	Age Moderates Associations of Hypertension, White Matter Hyperintensities, and Cognition. Journal of Alzheimer's Disease, 2020, 75, 1351-1360.	1.2	20
50	Creutzfeldt-Jakob disease: Which diffusion-weighted imaging abnormality is associated with periodic EEG complexes?. Journal of Neurology, 2008, 255, 1411-1414.	1.8	19
51	Differences Exist in the Cognitive Profile of Mild Alzheimer's Disease and Subcortical Ischemic Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2009, 27, 399-403.	0.7	19
52	Atrial Fibrillation is Independently Associated with Cognitive Impairment after Ischemic Stroke. Journal of Alzheimer's Disease, 2017, 60, 867-875.	1.2	19
53	Progression of small vessel disease correlates with cortical thinning in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 31, 34-40.	1.1	18
54	Altered Cerebrospinal Fluid Exosomal microRNA Levels in Young-Onset Alzheimer's Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease Reports, 2021, 5, 805-813.	1.2	18

#	Article	IF	CITATIONS
55	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. Frontiers in Pharmacology, 2019, 10, 1398.	1.6	17
56	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. Translational Neurodegeneration, 2021, 10, 11.	3.6	17
57	Neuropsychiatric symptoms in Southâ€East Asian patients with mild cognitive impairment and dementia: prevalence, subtypes, and risk factors. International Journal of Geriatric Psychiatry, 2018, 33, 122-130.	1.3	16
58	Cerebral white matter disease is independently associated with BPSD in Alzheimer's disease. Journal of the Neurological Sciences, 2014, 337, 162-166.	0.3	15
59	High burden of cerebral white matter lesion in 9 Asian cities. Scientific Reports, 2021, 11, 11587.	1.6	15
60	Early detection of dementia in multilingual populations: Visual Cognitive Assessment Test (VCAT). Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309647.	0.9	14
61	Targeted exome sequencing reveals homozygous TREM2 R47C mutation presenting with behavioral variant frontotemporal dementia without bone involvement. Neurobiology of Aging, 2018, 68, 160.e15-160.e19.	1.5	14
62	Baseline predictors of worsening apathy in Parkinson's disease: A prospective longitudinal study. Parkinsonism and Related Disorders, 2016, 23, 95-98.	1.1	13
63	A novel language-neutral Visual Cognitive Assessment TestÂ(VCAT): validation in four Southeast Asian countries. Alzheimer's Research and Therapy, 2018, 10, 6.	3.0	13
64	Getting Lost Behavior in Patients with Mild Alzheimer's Disease: A Cognitive and Anatomical Model. Frontiers in Medicine, 2017, 4, 201.	1.2	12
65	DTI Profiles for Rapid Description of Cohorts at the Clinical-Research Interface. Frontiers in Medicine, 2018, 5, 357.	1.2	12
66	Mechanisms Linking White Matter Lesions, Tract Integrity, and Depression in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2019, 27, 948-959.	0.6	12
67	Identification of novel candidate autoantibodies in Alzheimer's disease. European Journal of Neurology, 2020, 27, 2292-2296.	1.7	12
68	Construct validity of the Visual Cognitive Assessment Test (VCAT)—a cross-cultural language-neutral cognitive screening tool. International Psychogeriatrics, 2020, 32, 141-149.	0.6	10
69	The role of cerebral microbleeds in the incidence of post-stroke dementia. Journal of the Neurological Sciences, 2020, 412, 116736.	0.3	10
70	Small Vessel Disease and Associations with Cerebrospinal Fluid Amyloid, Tau, and Neurodegeneration (ATN) Biomarkers and Cognition in Young Onset Dementia. Journal of Alzheimer's Disease, 2020, 77, 1305-1314.	1.2	9
71	Association of Asymmetrical White Matter Hyperintensities and Apolipoprotein E4 on Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 70, 953-964.	1.2	8
72	Differential Effects of Confluent and Nonconfluent White Matter Hyperintensities on Functional Connectivity in Mild Cognitive Impairment. Brain Connectivity, 2020, 10, 547-554.	0.8	8

NAGAENDRAN KANDIAH

#	Article	IF	CITATIONS
73	Association between white matter hyperintensity load and grey matter atrophy in mild cognitive impairment is not unidirectional. Aging, 2021, 13, 10973-10988.	1.4	8
74	Confluent White Matter in Progression to Alzheimer Dementia. Alzheimer Disease and Associated Disorders, 2021, 35, 8-13.	0.6	8
75	Alzheimer's Disease THErapy With NEuroaid (ATHENE): AÂRandomized Double-Blind Delayed-Start Trial. Journal of the American Medical Directors Association, 2021, , .	1.2	8
76	Real-world evaluation of compliance and preference in Alzheimer's disease treatment. Clinical Interventions in Aging, 2015, 10, 1779.	1.3	7
77	Medial Temporal Atrophy in Amyloid-Negative Amnestic Type Dementia Is Associated with High Cerebral White Matter Hyperintensity. Journal of Alzheimer's Disease, 2019, 70, 99-106.	1.2	7
78	Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 31-37.	0.9	6
79	N-Methyl-D-Aspartate(NMDA) Receptor and Voltage-Gated Potassium Channel (VGKC) Antibody-Associated Encephalitides Presenting as First Episode Acute Psychosis. Frontiers in Psychiatry, 2019, 10, 913.	1.3	6
80	Mapping the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III. Quality of Life Research, 2019, 28, 131-139.	1.5	6
81	The splenial angle: a novel radiological index for idiopathic normal pressure hydrocephalus. European Radiology, 2021, 31, 9086-9097.	2.3	6
82	The Association Between Diabetes Mellitus and Mild Behavioral Impairment Among Mild Cognitive Impairment: Findings from Singapore. Journal of Alzheimer's Disease, 2021, 82, 411-420.	1.2	6
83	Interaction between APOE-ɛ4 and HMGB1 is associated with widespread cortical thinning in mild cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 225-226.	0.9	5
84	Influence of White Matter Hyperintensities on Baseline and Longitudinal Amyloid-β in Cognitively Normal Individuals. Journal of Alzheimer's Disease, 2021, 84, 91-101.	1.2	5
85	Clinical Aspects of Neurobehavioral Symptoms of Dementia. Dementia and Neurocognitive Disorders, 2020, 19, 54.	0.4	5
86	APOE4 and Confluent White Matter Hyperintensities Have a Synergistic Effect on Episodic Memory Impairment in Prodromal Dementia. Journal of Alzheimer's Disease, 2022, 87, 1103-1114.	1.2	5
87	Role of Cognitive Enhancer Therapy in Alzheimer's Disease with Concomitant Cerebral White Matter Disease: Findings from a Long-Term Naturalistic Study. Drugs in R and D, 2014, 14, 195-203.	1.1	4
88	Voluntary cognitive screening: characteristics of participants in an Asian setting. Clinical Interventions in Aging, 2015, 10, 771.	1.3	4
89	Suicidal ideation is common in autosomal dominant Alzheimer's disease atâ€risk persons. International Journal of Geriatric Psychiatry, 2020, 35, 60-68.	1.3	4

90 Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia. Journal of

#	Article	IF	CITATIONS
91	Serial position effects differ between Alzheimer's and vascular features in mild cognitive impairment. Aging, 2018, 10, 3866-3880.	1.4	4
92	Frontotemporal dementia and COVIDâ€19: Hypothesis generation and roadmap for future research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12085.	1.8	4
93	Dementia in Southeast Asia: influence of onset-type, education, and cerebrovascular disease. Alzheimer's Research and Therapy, 2021, 13, 195.	3.0	4
94	Case-control analysis of leucine-rich repeat kinase 2 protective variants in Alzheimer's disease. Neurobiology of Aging, 2018, 64, 157.e7-157.e9.	1.5	3
95	Interactions Between Acute Infarcts and Cerebrovascular Pathology Predict Poststroke Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 206-211.	0.6	3
96	High Diagnostic Utility Incorporating a Targeted Neurodegeneration Gene Panel With MRI Brain Diagnostic Algorithms in Patients With Young-Onset Cognitive Impairment With Leukodystrophy. Frontiers in Neurology, 2021, 12, 631407.	1.1	3
97	Importance of mental capacity: time for greater attention and action. Singapore Medical Journal, 2015, 56, 646-648.	0.3	3
98	Validation of the Visual Cognitive Assessment Test (VCAT) for the Early Diagnosis of Cognitive Impairment in Multilingual Population in Malaysia. Psych, 2022, 4, 38-48.	0.7	3
99	Cerebrovascular Disease Is a Risk for Getting Lost Behavior in Prodromal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 344-352.	0.9	2
100	Does healthâ€related quality of life in Asian informal caregivers differ between earlyâ€onset dementia and lateâ€onset dementia?. Psychogeriatrics, 2020, 20, 608-619.	0.6	2
101	Characterising mild behavioural impairment in Asian mild cognitive impairment and cognitively normal individuals. Alzheimer's and Dementia, 2020, 16, e045059.	0.4	2
102	Capgras Syndrome in the Young. Alzheimer Disease and Associated Disorders, 2020, 34, 94-96.	0.6	2
103	The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study. Clinical Interventions in Aging, 2021, Volume 16, 301-309.	1.3	2
104	Upregulated Blood miR-150-5p in Alzheimer's Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid-β, and Cerebral Atrophy. Journal of Alzheimer's Disease, 2022, 88, 1567-1584.	1.2	2
105	Economic Burden of Dementia in Singapore: Preliminary Results. Value in Health, 2014, 17, A767.	0.1	1
106	P3-249: VISUAL COGNITIVE ASSESSMENT TOOL (VCAT): A SCREENING TOOL FOR MULTILINGUAL SOCIETIES. , 2014, 10, P722-P723.		1
107	P2-316: Visual Cognitive Assessment Test (VCAT): A Novel Tool Useful for Multi-Lingual Populations and Early Detection of Alzheimer's Disease with Cerebrovascular Disease (CVD). , 2016, 12, P758-P761.		1
108	[P2–320]: RISK FACTOR PROFILES PREDICTING DELAYED VASCULAR COGNITIVE IMPAIRMENT IN YOUNG AND OLD ISCHEMIC STROKE SURVIVORS. Alzheimer's and Dementia, 2017, 13, P740.	0.4	1

#	Article	IF	CITATIONS
109	[P1–236]: CSF NEUROFILAMENT LIGHT CHAIN LEVELS CORRELATE WITH MARKERS OF MICROGLIAL ACTIVATION (YKLâ€40) AND GLOBAL COGNITIVE MEASURES IN MCI, ALZHEIMER's DISEASE, AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P334.	0.4	1
110	[P2–304]: DIFFERENTIATING FRONTAL VARIANT ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P734.	0.4	1
111	Development and validation of a brief visual based cognitive screening tool for dementia: the Visual Cognitive Assessment Test short-form (VCAT-S). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1122-1123.	0.9	1
112	Mild Behaviour Impairment Checklist (MBI): Is there a difference in ratings between patient and close informant?. Alzheimer's and Dementia, 2020, 16, e039239.	0.4	1
113	Posterior cortical atrophy syndrome: Asian study. Alzheimer's and Dementia, 2020, 16, e044452.	0.4	1
114	Baseline Neurodegeneration Influences the Longitudinal Effects of Tau on Cognition. Journal of Alzheimer's Disease, 2021, 82, 159-167.	1.2	1
115	Safety and Usefulness of Lumbar Puncture for the Diagnosis and Management of Young-Onset Cognitive Disorders. Journal of Alzheimer's Disease, 2022, , 1-10.	1.2	1
116	Correlation Between Plasma Oligomeric Amyloid-β and Performance on the Language Neutral Visual Cognitive Assessment Test in a Southeast Asian Population. Journal of Alzheimer's Disease, 2022, 89, 25-29.	1.2	1
117	P4-150: CAROTID INFLAMMATION IS ASSOCIATED WITH WHITE MATTER DISEASE AND COGNITIVE IMPAIRMENT POST STROKE. , 2014, 10, P843-P843.		0
118	P4-153: INFLUENCE OF SMALL VESSEL CEREBROVASCULAR DISEASE ON THE NEUROPSYCHOLOGICAL PERFORMANCE OF PATIENTS WITH EARLY ALZHEIMER'S DISEASE. , 2014, 10, P844-P846.		0
119	P2-345: DEMENTIA CAREGIVER BURDEN AMONG ASIANS: INFLUENCE OF DISEASE SEVERITY AND AGE OF ONSET. , 2014, 10, P605-P606.		0
120	P2-277: CAREGIVER PREFERENCE AND TREATMENT OUTCOMES IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE TREATED WITH ORAL OR TRANSDERMAL MONOTHERAPY: ANALYSIS OF PROSPECTIVE DATA FROM THE RECAP STUDY. , 2014, 10, P578-P578.		0
121	P4-088: EXECUTIVE DYSFUNCTION IS CORRELATED WITH DECREASED HIPPOCAMPAL VOLUMES IN COGNITIVELY INTACT PARKINSON'S PATIENTS. , 2014, 10, P815-P816.		0
122	P1-206: CONCISE COGNITIVE EVALUATION BATTERY (CCEB): A RELIABLE COGNITIVE BATTERY FOR MEMORY CLINIC. , 2014, 10, P378-P379.		0
123	P2-167: CEREBRAL WHITE MATTER HYPERINTENSITY IS ASSOCIATED WITH GREATER CEREBRAL ATROPHY AMONG PATIENTS WITH YOUNG ONSET DEMENTIA. , 2014, 10, P531-P532.		0
124	P3-109: RENAL DYSFUNCTION CONTRIBUTES TO EPISODIC MEMORY DEFICITS AND MEDIAL TEMPORAL ATROPHY IN EARLY DEMENTIA: PILOT STUDY. , 2014, 10, P668-P668.		0
125	P3-240: A PREDICTION SCALE FOR POST-STROKE COGNITIVE IMPAIRMENT. , 2014, 10, P720-P720.		0

8

#	Article	IF	CITATIONS
127	P2-119: Subjective cognitive complaints and objective memory deficits in a young-old community cohort. , 2015, 11, P527-P528.		0
128	P4-098: The role of chronic cerebrovascular diseases in the development of post-stroke cognitive impairment. , 2015, 11, P811-P813.		0
129	P2-191: Development and validation of a novel 3-dimensional computer-based cognitive evaluation tool for the early diagnosis of dementia. , 2015, 11, P565-P566.		0
130	P2-241: Role of specialist-primary care collaboration in the management of early dementia. , 2015, 11, P584-P585.		0
131	P2â€207: Prevalence of Family History of Dementia in a Specialist Youngâ€Onset Dementia Clinic Cohort. Alzheimer's and Dementia, 2016, 12, P700.	0.4	0
132	P4â€213: Progression of Cerebral Smallâ€Vessel Disease Correlates With Cortical Thinning and Cognitive Impairment in Parkinson's Disease. Alzheimer's and Dementia, 2016, 12, P1107.	0.4	0
133	P2â€198: Neuroanatomical Substrates of Semantic Language Processing in Chinese Speakers with Semantic Variant Primary Progressive Aphasia. Alzheimer's and Dementia, 2016, 12, P696.	0.4	0
134	P3â€183: HMGBâ€1 and Annexin A1: Important Mediators of Neuroinflammation in the Syndrome of Alzheimer's Dementia with Concomitant Cerebrovascular Disease. Alzheimer's and Dementia, 2016, 12, P890.	0.4	0
135	P3â€409: Quality of Life of Patients with Mild Dementia (QOLâ€Mild Dementia): Development of a Novel Instrument. Alzheimer's and Dementia, 2016, 12, P1008.	0.4	0
136	P4â€185: Structural Connectivity Analysis Reveals White Matter Integrity Aberrations in Highâ€Risk Cardiovascular Burden Subjects With Mild Alzheimer's Dementia. Alzheimer's and Dementia, 2016, 12, P1090.	0.4	0
137	O2-06-06: Higher Peripheral Trem2 Mrna Expression Levels are Related to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic MCI. , 2016, 12, P241-P241.		0
138	O3-01-03: Caring for Patients with Young Onset Dementia: What Factors Need Close Attention?. , 2016, 12, P280-P281.		0
139	P1â€054: Feasibility of Multidomain Cognitive Rehabilitation Incorporating Computerized 3â€Dimensional Virtual Technology for Persons With Dementia. Alzheimer's and Dementia, 2016, 12, P421.	0.4	0
140	[O1–13–04]: CROSSâ€CULTURAL EVALUATION OF A NOVEL LANGUAGEâ€NEUTRAL VISUALâ€BASED COGN EVALUATION TEST (VCAT) IN FOUR SOUTHEAST ASIAN POPULATIONS. Alzheimer's and Dementia, 2017, 13, P226.	ITIVE 0.4	0
141	[P2–551]: THE RELATIONSHIP OF HYPERTENSION, DIABETES AND OTHER VASCULAR RISK FACTORS WITH POSTSTROKE COGNITIVE FUNCTION: THE STROKOG (STROKE AND COGNITION) CONSORTIUM. Alzheimer's and Dementia, 2017, 13, P855.	0.4	0
142	[P3–468]: POOR SERIAL POSITION EFFECT PERFORMANCE IS CORRELATED WITH REDUCED CORTICAL AND HIPPOCAMPAL VOLUMES IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1152.	0.4	0
143	[P2–404]: HYPERTENSIVE VASCULOPATHY AS THE CAUSE OF CEREBRAL MICROBLEEDS IN PATIENTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P786.	0.4	0
144	[P3–432]: A VISUAL COGNITIVE ASSESSMENT TOOL FOR THE DIAGNOSIS OF YOUNGâ€ONSET DEMENTIA: A BIOMARKER‧UPPORTED STUDY. Alzheimer's and Dementia, 2017, 13, P1134.	0.4	0

#	Article	IF	CITATIONS
145	[P3–502]: DEVELOPMENT OF THE MDSâ€QOL: TOWARD A MORE RELEVANT QUALITYâ€OFâ€LIFE MEASURE IN DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1169.	MILD 0.4	0
146	[P4–320]: A MULTIDOMAIN STRUCTURED COGNITIVE STIMULATION PROGRAMME FOR ASIAN PATIENTS WITH MILD DEMENTIA: THE OWOW! PROGRAMME. Alzheimer's and Dementia, 2017, 13, P1412.	0.4	0
147	[ICâ€Pâ€092]: THE INDEPENDENT EFFECT OF CEREBRAL MICROBLEEDS ON COGNITION. Alzheimer's and Dementia, 2017, 13, P73.	0.4	0
148	[ICâ€Pâ€093]: HYPERTENSIVE VASCULOPATHY AS THE CAUSE OF CEREBRAL MICROBLEEDS IN PATIENTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P73.	0.4	0
149	[P1–390]: VOXELâ€BASED MORPHOMETRIC COMPARISON STUDY OF MILD COGNITIVE IMPAIRMENT IN ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. Alzheimer's and Dementia, 2017, 13, P416.	0.4	0
150	[P1–408]: CEREBROSPINAL FLUID TAU/AMYLOID β42 RATIO CORRELATES TO CEREBRAL ATROPHY IN AD. Alzheimer's and Dementia, 2017, 13, P431.	0.4	0
151	[P1–433]: THE INDEPENDENT EFFECT OF CEREBRAL MICROBLEEDS ON COGNITION. Alzheimer's and Dementia, 2017, 13, P447.	0.4	0
152	[P1–505]: ATRIAL FIBRILLATION IN ISCHEMIC STROKE SURVIVORS IS INDEPENDENTLY ASSOCIATED WITH EPISODIC MEMORY AND EXECUTIVE FUNCTION IMPAIRMENTS. Alzheimer's and Dementia, 2017, 13, P486.	0.4	0
153	[P1–568]: YOUNGâ€ONSET DEMENTIA IN A SOUTHEAST ASIAN POPULATION FROM SINGAPORE: CLINICAL ANE BIOMARKER CHARACTERIZATION. Alzheimer's and Dementia, 2017, 13, P512.	0.4	0
154	[P2–027]: LONGâ€ŢERM OUTCOMES OF A MULTIâ€ÐOMAIN COGNITIVE INTERVENTION AMONG ASIAN PATIEN WITH MILD DEMENTIA. Alzheimer's and Dementia, 2017, 13, P614.	ITS 0.4	0
155	[P2–337]: INTERACTION BETWEEN APOEɛ4 AND HMGB1 IS ASSOCIATED WITH CORTICAL THINNING IN MILD COGNITIVE IMPAIRMENT INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P750.	0.4	0
156	[O5â€"06â€"04]: RELEVANCE OF COMMUNITY COGNITIVE SCREENING: EXPERIENCE FROM SINGAPORE. Alzheimer's and Dementia, 2017, 13, P1468.	0.4	0
157	[O2–01–04]: SERIAL POSITION PROFILES OF RECALL IN MILD COGNITIVE IMPAIRMENT: INTERPLAY BETWEEN HIPPOCAMPAL VOLUMES AND WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P548.	0.4	0
158	P2â€339: MILD COGNITIVE IMPAIRMENT ASSOCIATED WITH PARKINSON'S DISEASE (PDâ€MCI) AND MCI ASSOCIATED WITH ALZHEIMER'S DISEASE (ADâ€MCI) HAVE DISTINCT COGNITIVE PROFILES: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P814.	0.4	0
159	P2â€ 340 : SUBSYNDROMAL DEPRESSION INTERACTS WITH AMYLOID TO PREDICT HYPOMETABOLISM AND CONSEQUENTLY COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P815.	0.4	0
160	P1â€353: CEREBROVASCULAR DISEASE IS ASSOCIATED WITH GETTING LOST BEHAVIOR IN MILD ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P429.	0.4	0
161	P2â€465: THE ROLE OF COMPREHENSIVE INVESTIGATION IN THE DIAGNOSTIC WORKâ€UP OF YOUNGER PATIEN WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P900.	rs 0.4	0
162	O4â€09â€05: MEDIAL TEMPORAL ATROPHY IN AMYLOIDâ€NEGATIVE, YOUNGâ€ONSET DEMENTIA IS ASSOCIATE	D WITH	0

HIGH WHITE MATTER HYPERINTENSITY. Alzheimer's and Dementia, 2018, 14, P1428.

#	Article	IF	CITATIONS
163	P2â€301: ELUCIDATING THE RELATIONSHIP BETWEEN NEUROPSYCHIATRIC SYMPTOMS AND COGNITIVE SUBSTRATES IN MILD ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P798.	0.4	0
164	P2â€570: FEASIBILITY OF VIRTUAL REALITY IN COGNITIVE ENHANCEMENT FOR PERSONS WITH YOUNG ONSET COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY. Alzheimer's and Dementia, 2018, 14, P954.	0.4	0
165	P3â€404: ACUTE INFARCTS INTERACT WITH PRE TROKE CEREBRAL AND VASCULAR PATHOLOGY TO PREDICT EARLYâ€ONSET DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1257.	0.4	0
166	P4â€139: EVALUATION OF COGNITIVE ENHANCEMENT AND COGNITIVE STIMULATION PROGRAMMES FOR ASIAN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1492.	0.4	0
167	P1â€586: DEVELOPMENT AND VALIDATION OF THE SQOL INSTRUMENT TO MEASURE QOL IN MILD DEMENTIA. Alzheimer's and Dementia, 2018, 14, P561.	0.4	0
168	P1â€342: SUICIDAL IDEATION IS PREVALENT IN BOTH ASYMPTOMATIC AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE MUTATION AND NONâ€MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P424.	0.4	0
169	P3â€468: CONSTRUCT VALIDITY OF THE VISUAL COGNITIVE ASSESSMENT TEST (VCAT): AN INTERNATIONAL LANGUAGEâ€NEUTRAL COGNITIVE SCREENING TOOL. Alzheimer's and Dementia, 2018, 14, P1299.	0.4	Ο
170	P1â€489: THE ADDITIVE VALUE OF NEUROPSYCHOLOGICAL EVALUATION, NEUROIMAGING, APOE GENOTYPING AND CEREBROSPINAL FLUID Aβ/TAU EVALUATION IN THE DIAGNOSIS OF YOUNGâ€ONSET DEMENTIA. Alzheimer' and Dementia, 2018, 14, P515.	s0.4	0
171	ICâ€Pâ€038: DIFFERENTIAL GREY AND WHITE MATTER MICROSTRUCTURAL ABNORMALITIES IN EARLY AND LATEâ€ONSET ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2019, 15, P43.	0.4	0
172	Differential effects of confluent and nonâ€confluent white matter hyperintensities on functional connectivity in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e038512.	0.4	0
173	Threshold of white matter hyperintensity volume determines negative and positive associations between grey matter volume and hypertension. Alzheimer's and Dementia, 2020, 16, e039298.	0.4	Ο
174	Assessing and improving primary care physician confidence in the recognition of youngâ€onset and atypical dementia: A pilot intervention. Alzheimer's and Dementia, 2020, 16, e039419.	0.4	0
175	Posterior cortical atrophy in Southeast Asia: Clinical and biomarker profile. Alzheimer's and Dementia, 2020, 16, e044223.	0.4	0
176	Cerebrovascular disease influences hippocampal subfield atrophy in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e045066.	0.4	0
177	Stroke memory rehabilitation (SMaRT) programme for mild ischemic stroke: Preliminary findings. Alzheimer's and Dementia, 2020, 16, e045709.	0.4	0
178	OWOW! Six years on, what have we learned? Experience and perspectives on a cognitive interventional programme for persons with dementia. Alzheimer's and Dementia, 2020, 16, e045977.	0.4	0
179	Amyloidâ€ŧauâ€neurodegeneration (ATN) profiles and influence of ageâ€ofâ€onset on cognitive trajectories in a Southeast Asian cohort: SYNC project. Alzheimer's and Dementia, 2021, 17, .	0.4	0
180	Findings from an Asian postâ€stroke cognitive impairment intervention programme. Alzheimer's and Dementia, 2021, 17, e055834.	0.4	0